{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:59:24Z","timestamp":1781207964413,"version":"3.54.1"},"reference-count":15,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,6,17]],"date-time":"2017-06-17T00:00:00Z","timestamp":1497657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Med Imag Rad Onc"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p><jats:sup>68<\/jats:sup>Ga\u2010<jats:styled-content style=\"fixed-case\">PSMA<\/jats:styled-content> positron emission tomography\u2013computed tomography (<jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content>) is useful for both staging and assessment of biochemical relapse in men with prostate cancer. Renal excretion of <jats:sup>68<\/jats:sup>Ga\u2010<jats:styled-content style=\"fixed-case\">PSMA<\/jats:styled-content> can lead to difficulties in scan interpretation, particularly in the pelvis. We evaluated if intravenous Frusemide at the time of <jats:sup>68<\/jats:sup>Ga\u2010<jats:styled-content style=\"fixed-case\">PSMA<\/jats:styled-content> injection reduces excreted activity artefact and improves diagnostic certainty.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Sixty\u2010two men with prostate cancer undergoing clinically indicated <jats:sup>68<\/jats:sup>Ga\u2010<jats:styled-content style=\"fixed-case\">PSMA PET<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content> were prospectively included, 30 men receiving Frusemide at the time of radiotracer injection. Clinical information and reasons for the scan were documented. Intensity of excreted activity was assessed semi quantitatively for each patient (<jats:styled-content style=\"fixed-case\">SUV<\/jats:styled-content> max). <jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content> images were interpreted by two experienced readers for image quality, and presence\/absence of <jats:styled-content style=\"fixed-case\">PSMA<\/jats:styled-content>\u2010positive disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty\u2010nine percent (18\/62) were staging scans, and 71% (44\/62) re\u2010staging. <jats:styled-content style=\"fixed-case\">PSMA<\/jats:styled-content>\u2010positive findings were identified in 95% (59\/62). Staging scans had <jats:styled-content style=\"fixed-case\">PSMA<\/jats:styled-content>\u2010positive findings within the prostate in 100% (18\/18) and re\u2010staging scans, 50% (22\/44) in the prostate fossa, 64% (28\/44) in lymph nodes and 21% (9\/44) in viscera and bone. Administration of Frusemide had a significant impact on intensity of excreted activity in the ureters and bladder. Impaired image quality was noted in 33% (10\/30) of men not given Frusemide, compared to only 3% (1\/32) in men given Frusemide (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.002). Reporter confidence on the presence\/absence of <jats:styled-content style=\"fixed-case\">PSMA<\/jats:styled-content> avid disease in the prostate fossa improved from 63% (19\/30) without Frusemide, to 91% (29\/32) with Frusemide (<jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.015).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Intravenous Frusemide given with <jats:sup>68<\/jats:sup>Ga\u2010<jats:styled-content style=\"fixed-case\">PSMA<\/jats:styled-content> reduces excretion artefact, and improves diagnostic certainty. Frusemide should be considered for all <jats:sup>68<\/jats:sup>Ga\u2010<jats:styled-content style=\"fixed-case\">PSMA PET<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content> imaging protocols.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1754-9485.12625","type":"journal-article","created":{"date-parts":[[2017,6,17]],"date-time":"2017-06-17T23:26:48Z","timestamp":1497742008000},"page":"739-744","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Frusemide aids diagnostic interpretation of <sup>68<\/sup>Ga\u2010<scp>PSMA<\/scp> positron emission tomography\/<scp>CT<\/scp> in men with prostate cancer"],"prefix":"10.1111","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3964-7771","authenticated-orcid":false,"given":"Niall","family":"Fennessy","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine St Vincent's Public Hospital Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine St Vincent's Public Hospital Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine St Vincent's Public Hospital Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine St Vincent's Public Hospital Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Aman","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine St Vincent's Public Hospital Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Royce","family":"Paschkewitz","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine St Vincent's Public Hospital Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[{"name":"University of New South Wales Sydney New South Wales Australia"},{"name":"Garvan Institute of Medical Research Darlinghurst New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,17]]},"reference":[{"key":"e_1_2_5_2_1","first-page":"55","article-title":"Prostate specific membrane antigen\u2010 a target for imaging and therapy with radionuclides","volume":"9","author":"Bouchelouche K","year":"2010","journal-title":"Discov Med"},{"key":"e_1_2_5_3_1","first-page":"6357","article-title":"Correlation of primary tumor prostate\u2010specific membrane antigen expression with disease recurrence in prostate cancer","volume":"9","author":"Ross JS","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.154153"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2016.26"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13540"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13397"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2298-2"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-014-0301-z"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.160382"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000277"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2949-6"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-013-2525-5"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-016-4308-4"},{"key":"e_1_2_5_15_1","first-page":"228","article-title":"Intravenous furosemide injection during 18F\u2010FDG PET acquisition","volume":"34","author":"L\u00f3pez\u2010Gandul S","year":"2006","journal-title":"J\u00a0Nucl Med Technol"},{"key":"e_1_2_5_16_1","first-page":"1352","article-title":"Optimization of urinary FDG excretion during PET imaging","volume":"40","author":"Moran JK","year":"1999","journal-title":"J Nucl Med"}],"container-title":["Journal of Medical Imaging and Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1754-9485.12625","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1754-9485.12625","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T16:49:36Z","timestamp":1696006176000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1754-9485.12625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,17]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1111\/1754-9485.12625"],"URL":"https:\/\/doi.org\/10.1111\/1754-9485.12625","archive":["Portico"],"relation":{},"ISSN":["1754-9477","1754-9485"],"issn-type":[{"value":"1754-9477","type":"print"},{"value":"1754-9485","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,17]]},"assertion":[{"value":"2016-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}